If you're not sure which of these trials might be right for you, contact our ALS Research Access Nurse for guidance.

Enrolling ALS Clinical Trials

Trial of BIIB067 for SOD1-ALS

Full Trial Name: A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis
Trial Phase: 3

We are doing this research study to find out about the safety and tolerability of the study drug BIIB067. The study is funded by Biogen MA Inc. This study is recruiting patients with SOD1-Amyotrophic Lateral Sclerosis (SOD1-ALS) with a forced vital capacity greater than or equal to 50% of predicted value. Participation in the study will last for approximately 31 weeks and will include an overnight stay at MGH in addition to in person visits. The study team can provide additional information on the number of required visits during your initial visit. There are additional inclusion/exclusion criteria that the study team will review with you in more detail.

Principal Investigator: Suma Babu, MD, MPH
Sponsor: Biogen MA Inc.
Enrollment Contacts:
Harli Weber, 617-643-5376 or hweber1@mgh.harvard.edu
Jenna Doherty, 617-643-0321 or jdoherty30@mgh.harvard.edu
Yuriko Fukumura, 617-643-2522 or yafukumura@mgh.harvard.edu

Trial of RNS60 for ALS

Full Trial Name: Effects of RNS60 on ALS Biomarkers
Trial Phase: 2

We are doing this trial to find out the effects of RNS60 on biomarkers in people with amyotrophic lateral sclerosis (ALS). Biomarkers are substances in the body that can be measured and evaluated as indicators of the body’s biological processes. We will study components in blood that may be affected by RNS60 and how it might be related to ALS. People who enroll in this trial will receive either RNS60 or placebo for 24 weeks. During this time, you will be asked to make weekly in-person study visits to MGH. You will also receive a supply of RNS60 or placebo to take at home once per day using a nebulizer.

Principal Investigator: Sabrina Paganoni, MD
Sponsor: Revalasio Corporation
Enrollment Contact: Reagan Church, 617-726-4284 or rmchurch@mgh.harvard.edu

Trial of Tregs for ALS

Full Trial Name: A Randomized, Placebo-Controlled Phase IIa Trial to Evaluate the Biological Activity, Safety, and Tolerability of Autologous Regulatory T Lymphocytes (Tregs) Expanded Ex-Vivo and Returned Intravenously in Combination with Low-Dose IL-2 in People with Amyotrophic Lateral Sclerosis (ALS)
Trial Phase: 2a

We are doing this Phase I research study to find out if infusions of your own Regulatory T Cells (Tregs), after being grown in a special laboratory, in combination with injections of Interleukin-2 or IL-2 (an immune stimulating drug) are safe, tolerable, can potentially improve Tregs numbers and function in your blood, and slow the progression of patients with Amyotrophic Lateral Sclerosis (ALS). This study is divided into two stages. In the first stage, the study will be placebo-controlled, which means that some participants will receive study medication that contain no active study medication.

The study is recruiting for patients with a diagnosis of Amyotrophic Lateral Sclerosis who have a slow vital capacity of >/= 65%. The total time for study participation will be approximately 70 weeks. You will receive the study drug for a total of 58 weeks. During this time, we will ask you to make up to 25 study visits to the clinic and 12 phone calls. You will also be asked to fly to Houston Methodist Hospital and stay overnight as a part of your participation. You will be reimbursed for all travel costs associated with this trip.

There are additional inclusion/exclusion criteria that the study team will review with you in more detail if you are interested in participating.

Principal Investigator: James Berry, MD, MPH
Sponsors: ALS Association, ALS Finding a Cure, MDA Foundation Enrollment

For more information regarding this trial, or to further discuss how to participate, please contact one of the following study coordinators:
Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu
Reagan Church, 617-726-4284 or rmchurch@mgh.harvard.edu

 

Trial of BIIB078 for C9ORF72-ALS

Full Trial Name: A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis
Trial Phase: 1

We are doing this research study to find out about the safety and tolerability of the study drug BIIB078. The study is funded by Biogen MA Inc. This study is recruiting patients with C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) with a slow vital capacity greater than or equal to 50% of predicted value. Participation in the study will last for approximately 40 weeks and will include an overnight stay at MGH in addition to in person visits. The study team can provide additional information on the number of required visits during your initial visit. There are additional inclusion/exclusion criteria that the study team will review with you in more detail if you are interested in participating. For more information regarding this trial, or to further discuss how to participate, please contact the following study coordinator:

Principal Investigator: Suma Babu, MD, MPH
Sponsor: Biogen MA Inc.
Enrollment Contacts:
Harli Weber, 617-643-5376 or hweber1@mgh.harvard.edu
Yuriko Fukumura, 617-643-2522 or yafukumura@mgh.harvard.edu

Trial of BIIB100 for ALS

Full Trial Name: Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With ALS
Trial Phase: 1

We are doing this Phase I research study to find out about the safety and tolerability of the study drug BIIB100. BIIB100 is taken orally. This study is placebo-controlled, which means that some participants will receive study medication that contain no BIIB100.

The study is recruiting for patients with a diagnosis of Amyotrophic Lateral Sclerosis who have a slow vital capacity of >65%.

Participation in the study will last for 6 weeks and will include a 2-night overnight stay at MGH in addition to 2-3 in-person visits. During the overnight stay, you will receive a single dose of the study medication.

There are additional inclusion/exclusion criteria that the study team will review with you in more detail if you are interested in participating. For more information regarding this trial, or to further discuss how to participate, please contact one of the study coordinators.

Principal Investigator: Dr. Katharine Nicholson.
Sponsor: Biogen MA, Inc.
Enrollment Contacts:
Isabel Anez, 617-643-2499, ianezbruzual@mgh.harvard.edu
Yuriko Fukumura, 617-643-2522, yafukumura@mgh.harvard.edu

Enrolling Studies: Clinical Research to Understand ALS

Study of ALS Sample Repository (Living Library)

Recruiting: Healthy Volunteers, Non-ALS Neuro Disease Volunteers, Motor Neuron Disease Volunteers
Full Trial Name: ALS Sample Repository

We are developing a diverse living library of biofluid samples (blood, spinal fluid, urine) from people of different ages, ethnicities, and sexes, from healthy volunteers, people with amyotrophic lateral sclerosis (ALS), and motor neuron disease (MND), as well as other neurological diseases that may mimic motor neuron diseases. The samples collected will be stored and used for ALS research conducted globally to answer questions related to cause, prevention, treatment, and hereditability of ALS. Participants must be at least 20 years of age and be able to answer brief questions about their medical and family history, as well as be willing to have blood and/or CSF drawn for the study.

Principal Investigator: James Berry, MD, MPH
Sponsor: Project ALS, Winthrop Family Scholar in ALS Research and Clinical Care
Enrollment Contact: Alanna Farrar, 617-726-4282 or alfarrar@mgh.harvard.edu

Study of ANSWER ALS App

Recruiting: Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis patients

Full Trial Name: Smartphone Application and Wearable Activity Monitor to Track Progression of Amyotrophic Lateral Sclerosis
The purpose of this research study is to see if progression of diseases in people with Amyotrophic Lateral Sclerosis (ALS) can be tracked using a smart phone application (app) over time. You are being asked to participate because you are already enrolled in Answer ALS and this is a sub-study of that study.
There are 7 tasks in the app. You will be asked to perform one task a day. The tasks are:

  • Voice recording
  • Finger tapping - Right and Left
  • Finger tracing - Right and Left
  • Tilt tracing - Right and Left

We are asking that you continue to use the app for as long as you are able. The duration of this study is approximately 12 months. During this time, you will have two in person visits and I will contact you by phone or email in 2 weeks and then again at months 2, 6, and 9 months to see if you are having any issues and to get any feedback about the app you would like to contribute. Please contact us if you are interested in hearing more details and/or if you would like to know if you are eligible to participate in this study.

Principal Investigator: James Berry, MD, MPH
Sponsors: ALS Finding a Cure, The Robert Packard Center, The Answer ALS Foundation
Enrollment Contact: Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu

Study of DIALS

Recruiting: Asymptomatic first-degree adult relatives of people with familial ALS
Full Trial Name: Dominant Inherited ALS (DIALS) Network

This study is recruiting participants who do not have any neurological symptoms, but who have a first-degree relative with ALS caused by a mutation. The purpose of the research study is to study a population at risk for developing ALS. The information collected in this study will further our understanding of underlying early disease changes to allow for development of novel therapeutics that target the earliest changes in ALS and allow for possible disease prevention.
Through this study you will be offered genetic counseling, and genetic testing for all currently known genes that may cause ALS. In addition, the study will be performing regular, longitudinal evaluations (e.g. blood samples, questionnaire completion; pulmonary and strength testing etc.,) for a period of several years.  Study visits will be completed at the Neurological Clinical Research Institute at Massachusetts General Hospital.

Principal Investigator: Katharine Nicholson, MD
Sponsor: ALS Finding a Cure, Target ALS, ALS Association, American Academy of Neurology/Muscular Dystrophy Association
Enrollment Contact: Isabel Anez, 617-643-2499 or ianezbruzual@mgh.harvard.edu

Study of Digital Quantitative Measurements in ALS

Recruiting: ALS Patients & Healthy Volunteers

The purpose of this study is to test the feasibility and utility of digital quantitative measurements for people with ALS. Specifically, we aim to investigate the utility of digital tools to quantify the neurological exam in clinic. We are also investigating the utility of digital tools to quantify behavior outside of clinic.

This study is a week-long investigation looking at digital biomarkers. There is an in clinic visit where we will obtain your consent to participate in the study and ask you to complete a number of tasks, including a digital neurological exam. The study team will give you an Apple Watch and an iPhone to collect digital information about you for one week. At the end of the week, you will be asked to return to the clinic for another digital neurological exam.

Please contact us if you are interested in hearing more details and/or if you would like to know if you are eligible to participate in this study. Stipend for completion of study: $150

Principal Investigator: James Berry, MD, MPH
Sponsor: Biogen MA, Inc.
Enrollment Contacts:
Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu
Minhaj Rahman, 617-726-1880 or smrahman@mgh.harvard.edu

Study of Neuroinflammation (PBR28) Imaging

Recruiting: Patients with Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia or Frontotemporal Dementia
Healthy Volunteers Who Are Known Carriers of ALS Gene

Full Trial Name: Glial Activation Measured by PBR28-PET in People with Neurodegenerative Diseases
The purpose of the study is to learn more about inflammation in the brains of people with Motor Neuron Disease (MND) using combined Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). Our study will examine whether particular cells, called microglia, are hyperactive in the nervous system of people with MND, such as those individuals with ALS.

Study participation involves two visits to MGH over a maximum of three months. Participants must be between the ages of 18 and 80, be medically safe to undergo an MRI scan and be able to safely lie flat for at least 90 minutes. Additionally, participants cannot be taking any immunosuppressive medications or have a diaphragm pacing system and cannot have a diagnosis of Parkinson’s disease, Alzheimer’s disease, unstable psychiatric disease, or renal failure. All participants will be reimbursed for parking and receive compensation of $150 upon completion of each MR-PET scan. There will be additional compensation of $100 for each lumbar puncture completed by individuals with MND.

Principal Investigator:
 Suma Babu, MD, MPH
Sponsors: Neurodegenerative Disease Pilot Study Grant, K23 NS 083715, Evan and Arlene Yegelwel Endowed Fund for Primary Lateral Sclerosis Research and Care, PET Imaging of inflammation and epigenetics in ALS (ALS ONE), Muscular Dystrophy Association, Sundry
Enrollment Contacts:
LZ Bouzid, 617-643-6252 or zbouzid@mgh.harvard.edu
Dario Gelevski, 617-726-0563 or dgelevski@mgh.harvard.edu

Study of Skin Biopsy/Stem Cells for Research in MND

Recruiting: Patients with Amyotrophic Lateral Sclerosis or Primary Lateral Sclerosis, healthy volunteers
Full Trial Name: Stem Cells for Research in Motor Neuron Diseases (MND)

Neurodegenerative diseases are diseases in which nerve cells of the brain and spinal cord die. There is a need to understand the cause of these diseases and to develop treatments. Recent advancements in stem cell technology have allowed us to create a person’s own nerve cells by taking a skin biopsy or blood sample. This study wants to use this new technology to make models for neurodegenerative diseases. We hope this will give us a better understanding of the diseases, enable us to use the cells for drug screening, and in the future, develop treatments.

Principal Investigator: James Berry, MD, MPH
Sponsor: Harvard Stem Cell Institute
Enrollment Contacts:
Alanna Farrar, 617-726-4282 or alfarrar@mgh.harvard.edu 
Cassandra Lieberman, 617-643-7428 or Clieberman1@mgh.harvard.edu

Study of Smartphone App for ALS

Recruiting: Patients with Amyotrophic Lateral Sclerosis
Full Trial Name: Feasibility and Sensitivity of a Symptom Monitoring Application in Real Time (SMART) for Amyotrophic Lateral Sclerosis

The study asks each participant to use the smartphone application for a few minutes every day by answering a questionnaire/survey, recording your voice and/or performing an on-screen exercise. The purpose of the research study is to determine how helpful a smartphone application would be in collecting research data and to learn more about disease progression. This is a pilot study in which a smartphone application was designed and customized for use in ALS clinical trials.

Individuals with ALS will be in the study for about 12 months.

The study is currently recruiting participants who meet the following guideline: Adults with Amyotrophic Lateral Sclerosis (ALS) to download and use the smartphone application using their smartphone device running iOS 8 or higher, or Android 4.1 or higher.

Principal Investigator: James Berry MD, MPH
Sponsor: ALS Finding a Cure
Enrollment Contact: Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu

Study of SOD1 Kinetics

Recruiting: Patients with Amyotrophic Lateral Sclerosis, healthy volunteers
Full Trial Name: SOD1 Kinetics Measurements in SOD1 Positive ALS Patients

The purpose of this study is to find out how long the SOD1 protein stays in cerebrospinal fluid (CSF). The SOD1 protein is known to cause some forms of familial Amyotrophic Lateral Sclerosis (ALS). This study is recruiting adults with SOD1-confirmed Amyotrophic Lateral Sclerosis (ALS), Sporadic ALS (not caused by SOD1 gene), SOD1-positive asymptomatic gene carriers, and healthy adults with no medical history of neurological disease. This study involves drinking a special leucine labeled beverage for 10 days, which will be provided by the study team. Participation in this study will last approximately 4 months and requires 6 visits to MGH. Four of these visits will involve a lumbar puncture (LP). Participants must be 18 years of age, able to comply with study procedures, and be medically safe to undergo a lumbar puncture (LP).

Principal Investigator: Katharine Nicholson, MD  
Sponsor: ALS Finding a Cure
Enrollment Contacts:
Isabel Anez, 617-643-2499 or ianezbruzual@mgh.harvard.edu
Alanna Farrar, 617-726-4282 or alfarrar@mgh.harvard.edu

Study of Speech Motor Impairment in ALS

Recruiting: Patients with Amyotrophic Lateral Sclerosis or Primary Lateral Sclerosis, healthy volunteers
Full Trial Name: Speech Motor Impairments: Coordination of tongue, lips, and Jaw

The Speech and Feeding Disorders Lab at MGH Institute of Health Professions is interested in studying the movements the face and mouth during speech, chewing and swallowing in persons diagnosed with ALS and healthy volunteers. You will be asked to fill out a health questionnaire as well as to repeat various sounds and sentences while the movements of your face and mouth are recorded. This research aims to help improve the diagnosis and treatments of ALS, and to help develop new technologies that will help improve communication for people with speech impairments.
Principal Investigator: Jordan Green, MD
Sponsors: National Institutes of Health (NIH) and the American Speech-Language-Hearing Foundation (ASHA)
Enrollment Contact: Speech and Feeding Disorders Lab, 617-724-6347 or speechfeedinglab@mghihp.edu 

Study of SPINE-ALS

Recruiting: Patients with Amyotrophic Lateral Sclerosis and Healthy Volunteers
Full Trial Name: Positron Emission Tomography to Characterize in vivo Neuroinflammation in the Spinal Cord in People with ALS

We are doing this research to learn more about changes in the spinal cord and brain in ALS. “Microglia” are a type of immune cell that we are particularly interested in. We would like to find out if microglia are activated in the spinal cord and brain of individuals with ALS. Special imaging techniques are now available to test for changes in microglia. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are two tests that allow us to take pictures and “look inside” the body without surgery. MR-PET scanners use both MRI and PET tests at the same time. The MR-PET scanner may give clearer images and more information about the inside of the body.
If you choose to take part in this study you may have 2 visits at Mass General, up to 3 months apart. We will pay you $150 for completion of the spinal cord MR-PET scan. If you choose to participate in the optional brain MR-PET scan you will be paid an additional $50 for completion.

Principal Investigators: Suma Babu, MD, MPH
Sponsors: ALS Finding a Cure Foundation, Voyager Therapeutics
Enrollment Contacts:
LZ Bouzid, 617-643-6252 or zbouzid@mgh.harvard.edu
Dario Gelevski, 617-726-0563 or dgelevski@mgh.harvard.edu

Study of Typing in ALS

Recruiting: People with ALS, healthy volunteers

Full Trial Name: Evaluating nQ as an objective biomarker to assess fine motor impairment in patients with ALS.

The purpose of this study is to see if a smartphone keyboard can identify unique typing patterns in ALS and serve as a quantifiable, digital biomarker of fine motor change over time in people with ALS. This is a 9-month long study, with visits every 3 months. The visits include standard questionnaires and outcome measures, including muscle and breathing tests. The study team will help you download and install the nQ software on your smartphone. We will ask you to keep the software on your smartphone throughout the duration of the study.

The study is currently recruiting participants with ALS and healthy volunteers who use their smartphone for at least ~15 minutes every day.

Principal Investigator: James Berry MD, MPH
Sponsor: ALS Finding a Cure and nQ Medical, Inc.
Enrollment Contacts:
Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu
Minhaj Rahman, 617-726-1880 or smrahman@mgh.harvard.edu

Active, Enrollment Complete

Trial of NurOwn for ALS

Full Trial Name: A Phase 3, Randomized, Double-Blind, Placebo-controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administrations of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Patients with Amyotrophic Lateral Sclerosis
Trial Phase:
 3

The purpose of the study is to evaluate the safety and efficacy of transplanting self-derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) into the cerebrospinal fluid in patients with ALS. The cells are derived from your own bone marrow and administered into your cerebrospinal fluid three times (once every 8 weeks for 16 weeks). Participation in this study will last approximately 12 months.

Principal Investigator: James Berry, MD, MPH
Sponsor:
 Brainstorm Cell Therapeutics
Enrollment Contact: Reagan Church, 617-726-4284 or NurOwnPhase3@mgh.harvard.edu

Trial of ODM-109

Full Trial Name: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS Trial
Phase: 3

This Phase III research study is being done to evaluate if Levosimendan (ODM-109) can help with respiratory function in people with ALS. We also want to find out if levosimendan is safe to take without causing too many side effects in ALS. Orion Corporation Orion Pharma is the sponsor of this study. Levosimendan is contained in a capsule, which is taken orally. This study is placebo-controlled, which means that some participants will receive capsules that contain no levosimendan. Study participation will last approximately 12 months. Please contact the study team to obtain additional information about the study visits and procedures. The study team will review with the inclusion and exclusion criteria during the study, which is also available on clinicaltrials.gov.

Principal Investigator: Suma Babu, MD, MPH
Sponsor: Orion Corporation, Orion Pharma
Enrollment Contact: Ella Collins, 617-726-0981 or ecollins15@mgh.harvard.edu

Trial of AMX0035

Full Trial Name: Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Trial Phase: 2

This research study is being done to find out if AMX0035 can help with Amyotrophic Lateral Sclerosis (ALS). We also want to find out if AMX 0035 is safe to take without causing too many side effects. AMX0035, a combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), is not approved by the US Food and Drug Association (FDA). This means that AMX0035 can only be used in research studies. This is the first use of the combination drug AMX0035 in humans. However, the individual components of the drug, PB and TUDCA, have been studied in small clinical trials of patients with ALS. This research study will compare AMX0035 to placebo. Participants will receive study drug for a total of 24 weeks, followed by a telephone call about 30 days from the final study visit. During this time, we will ask participants to make up to seven study visits to the clinic and four telephone calls. Overall participants may be in the research study for about 8 months.

Principal Investigator: James Berry, MD, MPH
Sponsor: Amylyx Pharmaceuticals Inc.
Enrollment Contact: Minhaj Rahman, 617-726-1880 or smrahman@mgh.harvard.edu

Study of ANSWER-ALS

Study participants: Patients with Amyotrophic Lateral Sclerosis or Primary Lateral Sclerosis

Answer ALS is a research study that is helping to create the largest-ever collection of stem cell lines derived from the blood of people with ALS. The collection of cells will be linked to detailed clinical information and a repository of biospecimens. The cell lines and clinical data will be studied in laboratories from across the country that have partnered for this project. Data from these labs will be analyzed individually and together using “big data” analysis techniques to demonstrate why and how motor neurons are affected by ALS, to identify biologically unique subgroups of people with ALS, and to search for new targets for drug therapy.

Participants must be at least 18 years of age, and able to follow study tasks. Participants will be asked to come to MGH approximately every 3 months for 1 year, and will be followed by telephone thereafter for as long as they are willing.

Principal Investigator: James Berry, MD, MPH
Sponsor: ALS Finding a Cure
Enrollment Contact: Alanna Farrar, 617-726-4282 or alfarrar@mgh.harvard.edu

Study of TRACK-ALS

Study participants: Patients with Amyotrophic Lateral Sclerosis (>1 year of symptoms) and healthy volunteers
Full Trial Name: Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

TRACK-ALS is a multicenter, longitudinal study which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of disease pathology and progression. By identifying changes that occur in the blood, brain, and cerebrospinal fluid (CSF) of individuals with ALS, this pilot project has the potential to inform both diagnostic measures and drug development.

Participation in the study for those with ALS involves approximately six onsite visits to MGH every three months for up to 18 months. Healthy volunteers are asked to make up to two onsite visits to MGH over the course of approximately two months. At these visits, participants will undergo an MRI scan to enable researchers to look at structural changes in the brain. Participants will also have blood drawn for analysis of inflammatory markers and generation of stem cells for further research. Other outcome assessments for ALS participants include breathing tests, muscle tests, and questionnaires, as well as an optional lumbar puncture to enable researchers to analyze biomarkers in the CSF. Finally, a subset of participants will undergo PET scans, which allow researchers to identify regions of inflammation in the brain.

Participants must be between the ages of 18 and 80, be medically safe to undergo an MRI scan (i.e., no metallic particles in the body), and be able to safely lie flat for at least 90 minutes. Additionally, participants cannot be taking any immunosuppressive medications or have a diaphragm pacing system and cannot have a diagnosis of Parkinson’s disease, Alzheimer’s disease, unstable psychiatric disease, cognitive impairment, or renal failure.

Principal Investigators: Nazem Atassi, MD, MMSc, and Suma Babu, MD, MPH
Sponsors: ALS Association and Philanthropy
Enrollment Contact: Dario Gelevski, 617-726-0563 or dgelevski@mgh.harvard.edu